Trial reportSocial science & medicine (1982)2022
The relative contributions of biomarkers, disease modifying treatment, and dementia severity to Alzheimer's stigma: A vignette-based experiment.
Trial report in Social science & medicine (1982), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 36 citations in OpenAlex.
- How reactions to a brain scan result differ for adults based on self-identified Black and White race.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Trial
- Learning about a heightened genetic risk for dementia: Expected stigma is greater than experienced stigma.Psychology and aging · 2026Article
- Uncovering Hidden Patterns of Stigma Amongst Older Men With Urinary Incontinence: A Latent Profile Analysis.International journal of nursing practice · 2026Article
- Effects of caregiving experience on expectations of becoming an Alzheimer's disease caregiver in the future.The journals of gerontology. Series B, Psychological sciences and social sciences · 2026Article
- Recognizing Structural and Social Determinants of Health in the Diagnosis and Care of Dementia.Dementia (London, England) · 2026Article
- Public profiles in Alzheimer's disease stigma: Unsupported, discriminated, and alone.Journal of public health research · 2025Article
- Are Knowledge and Interpersonal Contact Cures for Alzheimer's Stigma? Data From Caregivers Offer Clues.Stigma and health · 2025Article
- Article
- Scope of anti-stigma programs against Alzheimer's disease: A scoping review.PLOS mental health · 2025Article
- A survey study of Alzheimer's stigma among Black adults: intersectionality of Black identity and biomarker diagnosis.Ethnicity & health · 2024Article
- Reasons for undergoing amyloid imaging among diverse enrollees in the A4 study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Double-Edged Sword: A Positive Brain Scan Result Heightens Confidence in an Alzheimer's Diagnosis But Also Leads to Higher Stigma Among Older Adults in a Vignette-Based Experiment.The journals of gerontology. Series B, Psychological sciences and social sciences · 2024Article
- Alzheimer disease blood biomarkers: considerations for population-level use.Nature reviews. Neurology · 2024Review
- Diagnosing Preclinical and Prodromal Neurodegenerative Diseases-The Clinical Is Political.JAMA neurology · 2024Article
- Alzheimer's in the modern age: Ethical challenges in the use of digital monitoring to identify cognitive changes.Informatics for health & social care · 2024Article
- Informing Alzheimer's Biomarker Communication: Concerns and Understanding of Cognitively Unimpaired Adults During Amyloid Results Disclosure.The journal of prevention of Alzheimer's disease · 2024Article
- The Room Where It Happens: Clinician Reflections on Returning Preclinical Alzheimer's Biomarker Results to Research Participants.The journal of prevention of Alzheimer's disease · 2024Observational
- The structural and social determinants of Alzheimer's disease related dementias.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023Review
- Preclinical Alzheimer Disease and the Electronic Health Record: Balancing Confidentiality and Care.Neurology · 2022Article
- Moving beyond disclosure: Stages of care in preclinical Alzheimer's disease biomarker testing.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
objectiveThe symptoms and prognosis of Alzheimer's disease (AD) dementia contribute to the public's negative reactions toward individuals with AD dementia and their families. But what if, using AD biomarker tests, diagnosis was made before the onset of dementia, and a disease-modifying treatment was available? This study tests the hypotheses that a "preclinical" diagnosis of AD and treatment that improves prognosis will mitigate stigmatizing reactions.
methodsA sample of U.S. adults were randomized to receive one vignette created by a 3 × 2 × 2 vignette-based experiment that described a person with varied clinical symptom severity (Clinical Dementia Rating stages 0 (no dementia), 1 (mild), or 2 (moderate)), AD biomarker test results (positive vs negative), and disease-modifying treatment (available vs not available). Between-group comparisons were conducted of scores on the Modified Family Stigma in Alzheimer's Disease Scale (FS-ADS).
resultsThe sample of 1,817 adults had a mean age two years younger than that of U.S. adults but was otherwise similar to the general adult population. The response rate was 63% and the completion rate was 96%. In comparisons of randomized groups, mild and moderate symptoms of dementia evoked stronger reactions on all FS-ADS domains compared to no dementia (all p < 0.001). A positive biomarker test result evoked stronger reactions on all but one FS-ADS domain (negative aesthetic attributions) compared to a negative biomarker result (all p < 0.001). Disease-modifying treatment had no measurable influence on stigma (all p > 0.05).
conclusionsThe stigmas of dementia spill over into preclinical AD, and availability of treatment does not alter that stigma. Translation of the preclinical AD construct from research into practice will require interventions that mitigate AD stigma to preserve the dignity and identity of individuals living with AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.